Panitumumab plus trifluridine/tipiracil as anti‐ EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The randomized phase II VELO trial showed that the addition of panitumumab to trifluridine/tipiracil significantly improves progression-free survival (PFS) as compared to trifluridine/tipiracil in third-line therapy in patients with refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC). With longer follow-up, final overall survival results and posttreatment subgroup analysis are presented. Sixty-two patients with refractory RAS WT mCRC were randomly assigned to receive, as third-line therapy, trifluridine/tipiracil alone (arm A) or in combination with panitumumab (arm B). Primary endpoint was PFS; secondary endpoints included overall survival (OS) and overall response rate (ORR). Median OS was 13.1 months (95% CI 9.5-16.7) in arm A compared to 11.6 months (95% CI 6.3-17.0) in arm B (HR: 0.96, 95% CI 0.54-1.71, P = .9). To evaluate the impact of subsequent lines of treatment, subgroup analysis was performed for the 24/30 patients in arm A, that received fourth-line therapy after disease progression. Median PFS was 4.1 months (95% CI 1.44-6.83) for 17 patients treated with anti-EGFR rechallenge as compared to 3.0 months (95% CI 1.61-4.31) for seven patients that received other therapies (HR: 0.29, 95% CI 0.10-0.85, P = .024). Median OS from the start of fourth-line treatment was 13.6 months (95% CI 7.2-20), and 5.1 months (95% CI 1.8-8.3) for patients treated with anti-EGFR rechallenge vs other therapies, respectively (HR: 0.30, 95% CI 0.11-0.81, P = .019). Final results of the VELO trial support the role of anti-EGFR rechallenge in the continuum of care of patients with RAS/BRAF WT mCRC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Panitumumab plus trifluridine/tipiracil as anti‐<scp>EGFR</scp> rechallenge therapy in patients with refractory <scp><i>RAS</i></scp> wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase <scp>II VELO</scp> trial
- Date Crossref
- 30/06/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Campania "Luigi Vanvitelli" pays non établi dans la noticeUniversité ou école supérieure
-
European Institute of Oncology Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors pays non établi dans la noticeÉtablissement de santé
-
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" pays non établi dans la noticeÉtablissement de santé
-
Ospedale Monaldi pays non établi dans la noticeÉtablissement de santé
-
A. O. Ordine Mauriziano di Torino pays non établi dans la noticeÉtablissement de santé
-
University of Turin Department of Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Department of Precision Medicine Università degli Studi della Campania “Luigi Vanvitelli” Naples Italy pays non établi dans la noticeInstitution
-
Oncologia Medica pays non établi dans la noticeInstitution
-
UOC Oncologia pays non établi dans la noticeInstitution
University of Campania "Luigi Vanvitelli", Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors — European Institute of Oncology et Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.